50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Price Target & Analyst Ratings

$126.59
-0.69 (-0.54%)
(As of 09/27/2022 05:10 PM ET)
Add
Compare
Today's Range
$125.36
$129.45
50-Day Range
$127.28
$161.18
52-Week Range
$117.64
$169.98
Volume
538,952 shs
Average Volume
568,796 shs
Market Capitalization
$7.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$200.00

Jazz Pharmaceuticals Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$200.00
57.99% Upside
High Prediction$225.00
Average Prediction$200.00
Low Prediction$148.00
TypeCurrent
9/27/21 to 9/27/22
1 Month Ago
8/28/21 to 8/28/22
3 Months Ago
6/29/21 to 6/29/22
1 Year Ago
9/27/20 to 9/27/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
13 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$200.00$203.69$204.14$208.79
Predicted Upside57.99% Upside37.23% Upside39.87% Upside28.15% Upside
Get Jazz Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.


JAZZ Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jazz Pharmaceuticals Stock vs. The Competition

TypeJazz PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.68
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside55.59% Upside1,115.13% Upside32.80% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1044
80.31%
Underperform Votes
256
19.69%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/21/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Madhu Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$192.00 ➝ $148.00+7.37%
8/5/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$210.00 ➝ $204.00+34.95%
8/4/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$185.00 ➝ $188.00+23.42%
8/4/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$200.00 ➝ $210.00+36.67%
8/4/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$194.00 ➝ $191.00+24.73%
8/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$174.00 ➝ $187.00+22.12%
5/5/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$200.00 ➝ $225.00+44.91%
5/5/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$197.00 ➝ $193.00+22.59%
3/2/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Folkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
3/2/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$216.00 ➝ $214.00+56.63%
2/7/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ami Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$215.00+51.28%
1/20/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$180.00 ➝ $200.00+42.21%
10/5/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$200.00+57.22%
7/6/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Steinberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$220.00+20.79%
6/22/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$235.00 ➝ $250.00+41.07%
5/19/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
4/14/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$195.00 ➝ $202.00+23.69%
11/3/2020Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$171.00 ➝ $184.00+24.96%
7/30/2020Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
7/28/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform
6/18/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$165.00 ➝ $167.00+50.86%
5/6/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$155.00 ➝ $153.00+35.98%
3/12/2020Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$175.00 ➝ $166.00+53.65%
11/11/2019Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Umer Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












JAZZ Price Target - Frequently Asked Questions

What is Jazz Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Jazz Pharmaceuticals stock is Moderate Buy based on the current 2 hold ratings and 9 buy ratings for JAZZ. The average twelve-month price prediction for Jazz Pharmaceuticals is $200.00 with a high price target of $225.00 and a low price target of $148.00. Learn more on JAZZ's analyst rating history.

Do Wall Street analysts like Jazz Pharmaceuticals more than its competitors?

Analysts like Jazz Pharmaceuticals more than other Medical companies. The consensus rating for Jazz Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how JAZZ compares to other companies.

Do MarketBeat users like Jazz Pharmaceuticals more than its competitors?

MarketBeat users like Jazz Pharmaceuticals more than other Medical companies. 80.31% of MarketBeat users gave Jazz Pharmaceuticals an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does Jazz Pharmaceuticals's stock price have much upside?

According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 36.75% based on their 12-month price targets.

What analysts cover Jazz Pharmaceuticals?

Jazz Pharmaceuticals has been rated by BMO Capital Markets, HC Wainwright, Morgan Stanley, SVB Leerink, The Goldman Sachs Group, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:JAZZ) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.